Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study

Brodalumab, an interleukin‐17 receptor A inhibitor, demonstrated rapid and robust efficacy with a favorable safety profile in patients with moderate to severe plaque psoriasis. Here, we present data from a multicenter, open‐label extension study in patients with plaque psoriasis with/without psoriat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Yukie, Takatsu, Nobumichi, Ootaki, Kenji, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318217/
https://www.ncbi.nlm.nih.gov/pubmed/32275086
http://dx.doi.org/10.1111/1346-8138.15343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318217/
https://www.ncbi.nlm.nih.gov/pubmed/32275086
http://dx.doi.org/10.1111/1346-8138.15343

Ejemplares similares